Cancer risk with topical pimecrolimus and tacrolimus

Prescrire International

Volumn 14, Issue 80, 2005, Pages 223-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; TACROLIMUS;

ARTICLE; CANCER RISK; CHILDHOOD CANCER; CLINICAL PRACTICE; DOSE RESPONSE; DRUG CARCINOGENICITY; DRUG FATALITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHADENITIS; LYMPHOMA; NONHUMAN; PRESCRIPTION; RISK BENEFIT ANALYSIS; SKIN TUMOR; THYROID ADENOMA;

ADMINISTRATION, TOPICAL; ADULT; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; TACROLIMUS;

EID: 28644439450     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. U.S. Food and Drug Administration "Alert for healthcare professionals. Tacrolimus (marketed as Protopic)" 14 February 2005. Website http://www.fda.gov accessed on 22 February 2005.
2. U.S. Food and Drug Administration "Alert for healthcare professionals. Pimecrolimus (marketed as Elidel)" 30 March 2005. Website http://www.fda.gov accessed on 3 April 2005.
3. Prescrire Editorial Staff "Tacrolimus ointment" Prescrire Int 2004; 13 (71): 86-89.
4. Prescrire Editorial Staff "Pimecrolimus cream" Prescrire Int 2004; 13 (74): 209-212.